These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 34938634)

  • 1. Serum Reactive Oxygen Metabolites as a Predictor of Clinical Disease Activity Index, Simplified Disease Activity Index, and Boolean Remissions in Rheumatoid Arthritis Patients Treated With Biologic Agents.
    Nakajima A; Terayama K; Sonobe M; Akatsu Y; Saito J; Norimoto M; Taniguchi S; Kubota A; Aoki Y; Nakagawa K
    Cureus; 2021 Nov; 13(11):e19759. PubMed ID: 34938634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences in disease activity measures in patients with rheumatoid arthritis who achieved DAS, SDAI, or CDAI remission but not Boolean remission.
    Aletaha D; Wang X; Zhong S; Florentinus S; Monastiriakos K; Smolen JS
    Semin Arthritis Rheum; 2020 Apr; 50(2):276-284. PubMed ID: 31590930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants.
    Smolen JS; Aletaha D
    Arthritis Rheum; 2011 Jan; 63(1):43-52. PubMed ID: 21204103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of remission criteria in patients with rheumatoid arthritis treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs: results from a nationwide registry.
    Koh JH; Lee Y; Kim HA; Kim J; Shin K
    Ther Adv Musculoskelet Dis; 2022; 14():1759720X221096363. PubMed ID: 35586514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum level of reactive oxygen metabolites (ROM) at 12 weeks of treatment with biologic agents for rheumatoid arthritis is a novel predictor for 52-week remission.
    Nakajima A; Aoki Y; Sonobe M; Takahashi H; Saito M; Nakagawa K
    Clin Rheumatol; 2017 Feb; 36(2):309-315. PubMed ID: 27858176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What is the best target in a treat-to-target strategy in rheumatoid arthritis? Results from a systematic review and meta-regression analysis.
    Messelink MA; den Broeder AA; Marinelli FE; Michgels E; Verschueren P; Aletaha D; Tekstra J; Welsing PMJ
    RMD Open; 2023 Apr; 9(2):. PubMed ID: 37116986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum levels of reactive oxygen metabolites at 12 weeks during tocilizumab therapy are predictive of 52 weeks-disease activity score-remission in patients with rheumatoid arthritis.
    Nakajima A; Terayama K; Sonobe M; Aoki Y; Takahashi H; Akatsu Y; Saito J; Taniguchi S; Yamada M; Kubota A; Nakagawa K
    BMC Rheumatol; 2019; 3():48. PubMed ID: 31891116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial.
    Smolen JS; Szumski A; Koenig AS; Jones TV; Marshall L
    Arthritis Res Ther; 2018 Jan; 20(1):8. PubMed ID: 29338762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of rheumatoid arthritis composite disease activity indices and residual activity in a Brazilian multicenter study- REAL study.
    Santos IA; Donizeti Ribeiro de Oliveira R; Couto Luna Almeida S; Vargas-Santos AB; Balbino Chaves Amorim R; Monteiro Gomides AP; de Albuquerque CP; Barros Bertolo M; Brandão Resende Guimarães MF; da Costa Pinto MR; Gomes Resende G; Dalva Neubarth Giorgi R; de Carvalho Saciloto N; Radominski SC; Borghi FM; Rossi Bonfiglioli K; Carrico da Silva H; de Fatima L da Cunha Sauma M; Alves Pereira I; Werner de Castro GR; Viegas Brenol C; Machado Xavier R; Maria Henrique Mota L; Louzada-Junior P; da Rocha Castelar-Pinheiro G
    PLoS One; 2022; 17(9):e0273789. PubMed ID: 36174077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Relationship of the clinical efficiency of tocilizumab therapy to the serum level of matrix metalloproteinase-3 in patients with rheumatoid arthritis].
    Avdeeva AS; Aleksandrova EN; Novikov AA; Cherkasova MV; Panasyuk EY; Nasonov EL
    Ter Arkh; 2013; 85(5):24-9. PubMed ID: 23819335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Visualization of DAS28, SDAI, and CDAI: the magic carpets of rheumatoid arthritis.
    Futó G; Somogyi A; Szekanecz Z
    Clin Rheumatol; 2014 May; 33(5):623-9. PubMed ID: 24599677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of newly proposed remission cut-points for disease activity score in 28 joints (DAS28) in rheumatoid arthritis patients upon IL-6 pathway inhibition.
    Schoels M; Alasti F; Smolen JS; Aletaha D
    Arthritis Res Ther; 2017 Jul; 19(1):155. PubMed ID: 28676129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performances of Clinical Disease Activity Index (CDAI) and Simplified Disease Activity Index (SDAI) appear to be better than the gold standard Disease Assessment Score (DAS-28-CRP) to assess rheumatoid arthritis patients.
    Dhaon P; Das SK; Srivastava R; Dhakad U
    Int J Rheum Dis; 2018 Nov; 21(11):1933-1939. PubMed ID: 28608433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of remission definition on healthcare cost savings estimates for patients with rheumatoid arthritis treated with biologic therapies.
    Barnabe C; Thanh NX; Ohinmaa A; Homik J; Barr SG; Martin L; Maksymowych WP
    J Rheumatol; 2014 Aug; 41(8):1600-6. PubMed ID: 25028381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discontinuation of adalimumab after attaining disease activity score 28-erythrocyte sedimentation rate remission in patients with rheumatoid arthritis (HONOR study): an observational study.
    Hirata S; Saito K; Kubo S; Fukuyo S; Mizuno Y; Iwata S; Nawata M; Sawamukai N; Nakano K; Yamaoka K; Tanaka Y
    Arthritis Res Ther; 2013 Sep; 15(5):R135. PubMed ID: 24286472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. American College of Rheumatology/European League Against Rheumatism remission criteria for rheumatoid arthritis maintain reliable performance when evaluated in 44 joints.
    Kaneko Y; Kondo H; Takeuchi T
    J Rheumatol; 2013 Aug; 40(8):1254-8. PubMed ID: 23772077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multi-biomarker disease activity score can predict sustained remission in rheumatoid arthritis.
    Ma MHY; Defranoux N; Li W; Sasso EH; Ibrahim F; Scott DL; Cope AP
    Arthritis Res Ther; 2020 Jun; 22(1):158. PubMed ID: 32580789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance of Routine Assessment of Patient Index Data 3 (RAPID3) for assessment of rheumatoid arthritis in clinical practice: differential agreement of RAPID3 according to disease activity categories.
    Kim SK; Park SH; Bae J; Son JT; Choe JY
    Rheumatol Int; 2014 Sep; 34(9):1311-8. PubMed ID: 24832679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of different criteria sets on early remission and identifying its predictors in rheumatoid arthritis: results from an observational cohort (2009-2018).
    Xie W; Li J; Zhang Z
    Clin Rheumatol; 2020 Feb; 39(2):381-389. PubMed ID: 31709477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How much does Disease Activity Score in 28 joints ESR and CRP calculations underestimate disease activity compared with the Simplified Disease Activity Index?
    Fleischmann R; van der Heijde D; Koenig AS; Pedersen R; Szumski A; Marshall L; Bananis E
    Ann Rheum Dis; 2015 Jun; 74(6):1132-7. PubMed ID: 25143522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.